Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
PJ Roberts, CJ Der - Oncogene, 2007 - nature.com
Mitogen-activated protein kinase (MAPK) cascades are key signaling pathways involved in
the regulation of normal cell proliferation, survival and differentiation. Aberrant regulation of …
the regulation of normal cell proliferation, survival and differentiation. Aberrant regulation of …
Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway
JS Sebolt-Leopold - Clinical Cancer Research, 2008 - AACR
Among mammalian mitogen-activated protein kinase (MAPK) signaling cascades, the
extracellular signal-related kinase (ERK) pathway has received the most attention in the …
extracellular signal-related kinase (ERK) pathway has received the most attention in the …
[HTML][HTML] Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy
The mitogen-activated protein kinases (MAPK) pathway, often known as the RAS-RAF-MEK-
ERK signal cascade, functions to transmit upstream signals to its downstream effectors to …
ERK signal cascade, functions to transmit upstream signals to its downstream effectors to …
Targeting aberrant RAS/RAF/MEK/ERK signaling for cancer therapy
U Degirmenci, M Wang, J Hu - Cells, 2020 - mdpi.com
The RAS/RAF/MEK/ERK (MAPK) signaling cascade is essential for cell inter-and intra-
cellular communication, which regulates fundamental cell functions such as growth, survival …
cellular communication, which regulates fundamental cell functions such as growth, survival …
The MEK/ERK network as a therapeutic target in human cancer
R Barbosa, LA Acevedo, R Marmorstein - Molecular Cancer Research, 2021 - AACR
Abstract The RAS–RAF–MEK–ERK pathway is the most well-studied of the MAPK cascades
and is critical for cell proliferation, differentiation, and survival. Abnormalities in regulation …
and is critical for cell proliferation, differentiation, and survival. Abnormalities in regulation …
Recent progress on MAP kinase pathway inhibitors
DE Uehling, PA Harris - Bioorganic & medicinal chemistry letters, 2015 - Elsevier
Abstract The RAS–RAF–MEK–ERK, or ERK signaling pathway propagates signals through
an intracellular signal transduction cascade. Since approximately one third of human …
an intracellular signal transduction cascade. Since approximately one third of human …
The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction
The RAF–MEK–ERK mitogen-activated protein kinase (MAPK) cascade is aberrantly
activated in a diverse set of human cancers and the RASopathy group of genetic …
activated in a diverse set of human cancers and the RASopathy group of genetic …
[HTML][HTML] Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: current status in clinical trials
Y Song, Z Bi, Y Liu, F Qin, Y Wei, X Wei - Genes & diseases, 2023 - Elsevier
Molecular target inhibitors have been regularly approved by Food and Drug Administration
(FDA) for tumor treatment, and most of them intervene in tumor cell proliferation and …
(FDA) for tumor treatment, and most of them intervene in tumor cell proliferation and …
Recent developments in anti-cancer agents targeting the Ras/Raf/MEK/ERK pathway
KK Wong - Recent patents on anti-cancer drug discovery, 2009 - ingentaconnect.com
The Ras/Raf/MEK/ERK mitogen-activated protein kinase (MAPK) pathway mediates cellular
responses to different growth signals and is frequently deregulated in cancer. There are …
responses to different growth signals and is frequently deregulated in cancer. There are …
Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy
BB Friday, AA Adjei - Clinical cancer research, 2008 - AACR
The identification of intracellular signaling cascades important for the growth and survival of
cancer cells has led to the development of targeted cancer therapeutics aimed at blocking …
cancer cells has led to the development of targeted cancer therapeutics aimed at blocking …